Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27804946 | 0.98 | POLB (0.44) | POLBPKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5608309 | 0.87 | DPP4 (0.43) | DPP4THRBTSHRNAAADYRK3 | |
| SCHEMBL5179241 | 0.84 | POLB (0.50) | POLBPKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL12205975 | 0.83 | POLB (0.41) | POLBPKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5608432 | 0.83 | GRIN2D (0.43) | POLBPKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5608146 | 0.81 | POLB (0.41) | POLBPKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5608131 | 0.80 | TSHR (0.44) | DPP4THRBTSHRNAAADYRK3 | |
| SCHEMBL5607853 | 0.80 | PKM (0.41) | PKMDPP4THRBDPP8DPP9 | |
| SCHEMBL19608893 | 0.80 | DPP4 (0.40) | POLBDPP4THRBTSHRNAAA | |
| SCHEMBL25142188 | 0.79 | GRIN2D (0.44) | POLBPKMGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108503571-B | Synthetic method of vildagliptin | 无锡科华生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-108503571-B | Synthetic method of vildagliptin | 无锡科华生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-108658826-B | Method for preparing vildagliptin | 上海三牧化工技术有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-108658826-B | Method for preparing vildagliptin | 上海三牧化工技术有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-107793341-A | A kind of preparation method of vildagliptin intermediate | 江苏天士力帝益药业有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-8569250-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| EP-2247602-B1 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295860-A1 | ORGANIC COMPOUNDS | HASSIEPEN ULRICH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8252751-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2247602-A2 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100256080-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| CN-101747221-A | Method for preparing amino adamantane carboxylic acid compounds | UNIV GUANGDONG TECHNOLOGY | 2010-06-23 | — | — | CN | disclosed |
| WO-2009068531-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-RE39744-E1 | Adamantane derivatives and process for producing them | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-07-24 | — | — | US | disclosed |
| EP-1137635-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-6392104-B1 | CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| EP-1137635-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6166063-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034241-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2000-06-15 | — | — | WO | disclosed |
| EP-0927711-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM | Daicel Chemical Industries, Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256080-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | POLB 2799/4885PKM 1814/4885GRIN2D 3421/4885 |
| US-20120295860-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | POLB 2828/4885PKM 1830/4885GRIN2D 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.